Table 1.
Demographic and clinical characteristics at baseline of the 50 rheumatoid arthritis patients qualified for the treatment with TNF-α inhibitors.
| Parameter | Value |
|---|---|
| Age (years) | 47.52 ± 11.91 |
| Disease duration (years) | 6 (3–12) |
| Height (cm) | 163.58 ± 6.78 |
| Weight (kg) | 65.52 ± 14.40 |
| BMI (kg/m2) | 24.46 ± 5.17 |
| IgM-RF (+), n (%) | 44 (88) |
| Anti-CCP (+), n (%) | 43 (86) |
| ESR (mm/h) | 17.0 (10.0–29.0) |
| CRP (mg/L) | 6.37 (3.0–10.30) |
| SJC, n | 7 (5–10) |
| TJC, n | 12 (9–14) |
| VAS, (0–100 mm) | 80 (70–80) |
| DAS 28-ESR | 5.83 ± 0.49 |
| Anti-rheumatic drugs, n (%) | |
| MTX (25 mg/week) | 50 (100) |
| GC (≤7.5 mg/day) | 50 (100) |
| FA (5 mg/day) | 50 (100) |
| Calcium (1 g/day) | 50 (100) |
| 25-OH vitamin D (800–1000 IU/day) | 50 (100) |
| TNFαI therapy, n (%) | |
| ETA (Enbrel) | 24 (48) |
| ADA (Humira) | 22 (44) |
| CZP (Cimzia) | 2 (4) |
| GLM (Simponi) | 2 (4) |
Results are expressed as mean ± SD or median, inter-quartile (25th–75th percentile) range, or percentage (%). ADA, adalimumab; CZP, certolizumab pegol; DAS 28-ESR, disease activity score 28; ESR, erythrocyte sedimentation rate; ETA, etanercept; FA, folic acid; GC; glucocorticosteroid; GLM, golimumab; MTX, methotrexate; SD; standard deviation; SJC, swollen joint count; TJC, tender joint count; TNFαI, tumor necrosis factor α inhibitors; VAS, visual analogue scale.